Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.35 |
| ▸ | PDE4A | P27815 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180090 | 0.82 | RIPK1 (0.41) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL16744707 | 0.81 | MEN1 (0.34) | MEN1KMT2APOLBHTT | |
| SCHEMBL16744734 | 0.80 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL16744706 | 0.80 | MEN1 (0.41) | MEN1KMT2APOLBHTT | |
| SCHEMBL16744704 | 0.80 | MEN1 (0.41) | MEN1KMT2APOLBHTT | |
| SCHEMBL8168900 | 0.78 | HTR2C (0.34) | PDE4DPDE4APDE4BPDE4CSOS1 | |
| SCHEMBL16747607 | 0.78 | HTR2C (0.34) | PDE4DPDE4APDE4BPDE4CSOS1 | |
| SCHEMBL24180071 | 0.74 | RIPK1 (0.39) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL16744705 | 0.73 | PTPN2 (0.41) | POLB | |
| SCHEMBL31481195 | 0.72 | HSPB1 (0.45) | PDE4DPDE4APDE4BPDE4CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | PDE4D 2115/4885PDE4A 2184/4885PDE4B 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.